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Objectives. This study sought o establish the prognostic mpli- 
cations of ischemic and viable myocardium identified by dobut- 
amine echocardiography in patients with left veutricular dysfunc- 
tion. 
Background. Recent studies have suggested that in patients 
with viable myocardium identified by positron emission tomogra- 
phy, medical treatment is associated with recurrent cardiac 
events. Dobutamine chocardiography as been used to identify 
viable myocardium in patients with left ventricular dysfunction, 
but the prognostic significance of this test is undefined. 
Methods. One hundred thirty-six consecutive patients (mean 
[-+SD] age 67 + 7.9 years; 104 men) with moderate or severe left 
ventricular dysfunction (left ventricular ejection fraction 30 -+ 
5%) undergoing dobutamine chocardiography were included in 
the study. Dobntamine was administered using a standard incre- 
mental protocol (5 to 40/~g/kg body weight per rain intravenously 
in 3-rain stages) with additional atropine (1 mg intravenously) as 
required. Standard body weight echocardiographic views were 
digitized on-line and compared using a side-by-side display. 
Viable myocardium was identified by enhancement of regional 
function at low dose (<10 pg); scar was diagnosed by akinesia t 
rest or dyskinesia without change and ischemia as new or 
worsening dysfunction. One hundred thirty patients (95%) were 
followed up for 16 -+ 8 months after the original study for major 
cardiac events (cardiac death, myocardial infarction or severe 
unstable angina requiring late myocardial revascularization). 
Results. No significant complications occurred uring dobut- 
amine echocardiography. Viable myocardium was detected in 26 
patients (19%), ischemia in 23 (17%), both viability and ischemia 
in 13 (10%) and scar in 74 (54%). Of 108 patients treated med- 
ically, 46 had viable or ischemic myocardium, and 62 had scar 
only. There were no significant differences in age or other clinical 
characteristics, stress response, left ventricular dimensions and 
ejection fraction between the two groups. Cardiac events occurred 
in 26 medically treated patients (24%): 18 died of cardiac-related 
causes; 4 had a nonfatal myocardial infarction; and 4 had late 
revascularization because of unstable angina. The event rate was 
greater in patients with viable or ischemic myocardium than those 
with scar (43% vs. 8%, p = 0.01 by log-rank test). In a Cox 
regression model, the presence of viable or ischemic myocardium 
was found to predict subsequent events (relative risk 3.51, p = 
0.02) independently of ejection fraction and age. 
Conclusions. Viable or ischemic myocardium detected at dobut- 
amine echocardiography in patients with left ventricular dysfunc- 
tion is associated with an adverse prognosis, independent ofage 
and ejection fraction. 
(J Am Coll Cardiol 1996;27:132-9) 
The long-term outcome of patients with left ventricular dys- 
function can be predicted by clinical factors, the severity of left 
ventricular dysfunction and the presence of residual ischemic 
myocardium (1-3). Recent studies using myocardial metabolic 
imaging with positron emission tomography have shown (4-7) 
that the presence of residual viable myocardium is an adverse 
prognostic factor, with an effect additive to that of ischemia. 
Both ischemic and viable tissue may be jeopardized if perfused 
by a stenosed coronary vessel and are therefore susceptible to 
recurrent ischemic events. 
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Whereas positron emission tomography is expensive and 
not widely available; dobutamine stress echocardiography is an 
inexpensive and potentially widely available noninvasive test 
for the diagnosis and evaluation of coronary artery disease. In 
addition to its established role in the detection of ischemic 
responses in patients with normal left ventricular function 
(8-10), dobutamine chocardiography can distinguish viable 
from nonviable myocardium in patients with left ventricular 
dysfunction (11,12), and recent studies have demonstrated 
(13,14) concordance with positron emission tomography with 
respect o detection of viability. However, in addition to its 
diagnostic role, dobutamine echocardiography is often used for 
risk stratification, particularly for preoperative screening in 
patients who are unable to exercise (15-17). The purpose of 
the present study was to establish the prognostic implications 
of identifying both ischemia and viability with dobutamine 
echocardiography in patients with left ventricular dysfunction. 
~D 1996 by the American College of Cardiolog 3, 0735-1097/96/$15.00 
0735-1097(95)00393-i 
JACC Vol. 27, No. 1 WILLIAMS ET AL. 133 
January 1996:132-9 PROGNOSTIC VALUE OF DOBUTAMINE ECHOCARDIOGRAPHY 
Methods  
Patient selection. Over a 2-year period, 136 consecutive 
patients with known or suspected coronary artery disease and 
at least moderate rest left ventricular dysfunction and without 
valvular heart disease, recent myocardial infarction or myocar- 
dial revascularization (<3 months) underwent dobutamine 
eehocardiography. Patients with a left ventricular ejection 
fraction <40%, measured off-line, were enrolled for follow-up 
study. These patients represented the usual spectrum of clini- 
cal referrals for dobutamine echocardiography at our institu- 
tion and were tested either for preoperative risk stratification 
before noncardiac surgical intervention or for diagnosis or 
functional evaluation of coronary artery disease, particularly in
patients unable to exercise. 
Dobutamine stress testing. Dobutamine was administered 
according to a standard protocol (10), starting at 5 ~g/kg body 
weight per min and increasing to 10 ~g/kg per min after 3 min 
and then incrementally every 3 min to a maximum of 40/~g/kg 
per rain. Atropine (0.5 to 1.0 mg) was administered if heart 
rate at the 40-/~g/kg per rain dose was <85% of the age- 
predicted maximum, according to the equation: Predicted peak 
heart rate = 220 - Age. The test was performed with standard 
clinical, hemodynamic and electrocardiographic (ECG) moni- 
toring; symptoms, heart rate, blood pressure and 12-lead ECG 
were recorded every 2 to 3 min. The end points of the test were 
completion of the protocol, development of severe angina or 
extensive ischemia or occurrence of a severe side effect. 
Stress electrocardiography. Dobutamine stress ECG re- 
suits were interpreted as normal, ischemic or nondiagnostic. 
An ischemic response was defined as horizontal or downsloping 
ST segment depression or elevation >0.1 mV occurring in 
leads with normal baseline ST segment levels. A nondiagnostic 
response was identified in patients with left bundle branch 
block or >0.1-mV rest ST segment and T wave deviation, 
digitalis therapy or paced rhythm and a negative response in 
patients with <0.1-mV stress-induced ST segment depression. 
Eehocardiography. Echocardiographic images were ob- 
tained using standard equipment, and a full rest study was 
obtained for each patient before the start of dobutamine 
infusion. Rest left ventricular dimensions at end-diastole and 
end-systole were measured in the standard parasternal long- 
and short-axis views. Ejection fraction at rest was calculated 
from apical views using the modified Simpson's rule. 
Rest and stress images were digitized on-line in the 
parasternal long- and short-axis and apical four- and two- 
chamber views and placed in a cine loop, quad-screen format 
(ImageVue, Nova Microsonics). The four screens were succes- 
sively filled with the rest, two low dose (5 and 10 p~g) and peak 
dose (usually 40 ~g) images. 
Echoeardiographic image analysis was performed by consen- 
sus of two investigators experienced in the interpretation of
stress echocardiographic images and with no knowledge of 
both the clinical data and stress ECG findings. The interpre- 
tation was based on side-by-side comparison of images in the 
quad-screen digital display, as well as review of other cardiac 
cycles, including off-axis projections, from videotaped images. 
Analysis of regional left ventricular function was performed on 
a segmental basis using a standard 16-segment model, with 
regional wall scoring categorized asfollows: 1 = normal; 2a = 
mild hypokinesia; 2b = severe hypokinesia; 3 = akinesia; and 
4 = dyskinesia. Ischemia was defined as the development of a 
new or worsening wall motion abnormality in one segment or 
two adjacent segments if the basal inferior or posterior wall 
was involved, or if the segments were adjacent to significant 
scar, in which case the possibility of tethering could interfere 
with interpretation. Viable myocardium was defined as an 
improvement of thickening in at least one segment with rest 
hypokinesia or akinesia that occurred at the low to intermedi- 
ate dose (5 to 20 ~g). If these segments showed eterioration 
at peak dose, then this biphasic response was interpreted as 
showing both viability and ischemia. Myocardial scar was 
identified in segments with rest akinesia or dyskinesia that 
showed no thickening in response to dobutamine; however, 
these segments often had passive movement from tethering of 
normal hyperkinetic adjacent segments. Segments that were 
normal or mildly hypokinetic at rest and improved in the 
normal hyperkinetic manner in line with the overall segmental 
response were described as normal. 
Follow-up. Patients were followed up by telephone, mail, 
chart review or contact with the treating physician after a 
minimal interval of 6 months. Follow-up data were available 
for 130 (96%) of the 136 patients after a period of 16 _+ 8 
months (mean _+ SD). Events were defined as death, myocar- 
dial infarction or late myocardial revascularization due to 
unstable angina. In patients who died in-hospital or at home, 
the cause of death was elucidated from the medical record, the 
family and the local physician who signed the death certificate. 
A designation of cardiac death required documentation f
significant arrhythmia or cardiac arrest, or both, or death 
attributable tocongestive cardiac failure or myocardial infarc- 
tion in the absence of any other precipitating factors. In the 
small number of deaths out of hospital for which no autopsy 
was performed, sudden unexpected death was attributed to a 
cardiac cause. No attempt was made to further subclassify 
cardiac deaths into those due to arrhythmia or heart failure 
because of acknowledged limitations in this area, particularly 
the inability to determine the terminal event in patients with 
precedent progressive failure followed by arrhythmia. Myocar- 
dial infarction was defined as a cardiac event requiring admis- 
sion to hospital, with development of new ECG changes and 
cardiac enzyme level increase (creatine kinase >200 U). 
Hospital admissions for unstable angina or congestive cardiac 
failure were also documented but not considered "hard" 
cardiac end points if late revascularization was not provoked. 
Statistical analysis. Baseline clinical and echocardio- 
graphic characteristics are given as mean value _+ SD for 
continuous variables and as number (percent) for categoric 
variables. Patients were classified into those with myocardial 
scar only and those with either viability or ischemia on 
dobutamine echocardiography. Differences in continuous vari- 
ables were compared using the Student t test, whereas differ- 
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ences of categoric variables were compared using the chi- 
square test; p < 0.05 was considered significant. 
Patients were then classified into two groups according to 
the occurrence of events during the follow-up period. Clinical 
and echocardiographic variables were again compared in a 
similar manner. To analyze the impact of dobutamine cho- 
cardiographic results on cardiac prognosis, cumulative survival 
estimates were plotted according to the presence or absence of 
viability or ischemia using the Kaplan-Meier technique. Dif- 
ferences between survival curves were tested with the log-rank 
chi-square statistic. To adjust for potential confounding from 
effects of age and ejection fraction, which were postulated to 
be the two most important predictors of prognosis aside from 
the dobutamine echocardiographic variables, the Cox propor- 
tional hazards model (18) was used. The proportional hazards 
assumption was found to be valid by constructing a plot of the 
logarithm of the cumulative hazard over time, as described by 
Christensen (19). Proportional hazards and Kaplan-Meier 
analyses were performed using the PHREG and LIFETEST 
procedures of the SAS 6.08 statistical package (20,21). 
Results  
Clinical characteristics. Of 136 patients included in the 
study (104 men, 32 women; mean age [_SD] 67 _+ 7.9 years, 
range 48-87; mean ejection fraction 30 + 5%), 55 were 
referred for dobutamine echocardiography as part of a preop- 
erative valuation, 35 with known coronary artery disease and 
an inability to exercise were referred for testing as part of usual 
follow-up rotocols, 34 were referred for diagnosis of coronary 
disease in the presence of left ventricular dysfunction, and, in 
the latter stages of the study, 12 were referred directly for 
viability assessment aspart of a preintervention workup. One 
hundred twenty patients (92%) had a previous documented 
myocardial infarction or ECG and echocardiographic evidence 
of infarction, and 44 (32%) had undergone previous bypass 
surgery. 
Of 16 patients with left ventricular dysfunction without 
infarction, 14 had abnormal ECG responses at rest (left bundle 
branch block in 7, left ventricular hypertrophy and T wave 
inversion in 5, paced rhythm in 2), 3 had inducible abnormal 
responses on echocardiography, and 3 had evidence of signif- 
icant coronary disease at catheterization. Approximately 10 
patients had nondiagnostic ECG responses and no echocar- 
diographic regional wall motion abnormalities, and in the 
absence of catheterization data, may have had either ischemic 
or dilated cardiomyopathy. 
Coronary angiography was performed in 88 patients within 
12 months of dobutamine chocardiography. Triple-vessel or 
diffuse native coronary disease was present in 45 patients, 
predominant single- or double-vessel disease in 36 and no 
significant obstruction i  7 (5 of these 7 showed echocardio- 
graphic regional wall motion abnormalities). 
Dobutamine stress testing. There was no significant aug- 
mentation in systolic blood pressure in the overall group in 
response to dobutamine (rest 138 _+ 23 mm Hg vs. peak 
dobutamine dose 141 _+ 28 mm Hg), probably reflecting a 
number of patients with a moderate hypotensive response 
countering those with the anticipated increase in systolic 
pressure. Heart rate increased from 77 ~ 11 beats/rain at rest 
to 127 _+ 13 beats/rain at peak dobutamine dose; 81 patients 
(60%) achieved a heart rate response >85% age-predicted 
maximum. A total of 55 patients (40%) had an inadequate 
heart rate response (85% of age-predicted maximum) despite 
attainment of the peak dobutamine dose in 29. The submaxi- 
mal responses were ascribed to early termination from side 
effects (15 patients), ischemia (11 patients), beta-adrenergic 
blocker therapy (10 patients), AV node disease with perma- 
nent pacemakers (2 patients) and unexplained causes (17 
patients). 
Ninety-four patients attained the peak dose of dobutamine 
(40/xg/kg per rain). Despite selection of patients with moder- 
ate and severe left ventricular dysfunction, no major compli- 
cations occurred during dobutamine stress testing. Five pa- 
tients had nonsustained ventricular tachycardia, the maximal 
duration of which was 12 beats, without hemodynamic com- 
promise. Five patients had nonsustained atrial tachycardia, nd 
one developed atrial fibrillation that lasted for 2 h without 
notable compromise and reverted spontaneously to sinus 
rhythm. Test termination due to hypotension was more com- 
mon earlier in the series; subsequently, hypotension without 
concurrent symptoms or other abnormalities was not used as 
an end point unless it was severe (systolic blood pressure 
<100 mm Hg). Furthermore, the use of atropine may have 
alleviated some vagal responses, allowing completion of the 
test protocol. 
Dobutamine chocardiography. Of the 136 patients in the 
initial group who underwent dobutamine echocardiography, 26 
(19%) were diagnosed as having viable myocardium only, 23 
(17%) had an ischemic response only, and 13 (10%) had both 
viability and ischemia. Sixty-two patients therefore had evi- 
dence of myocardial viability or ischemia, or both. Fifty-seven 
(92%) of these 62 patients had involvement of two or more 
segments, with single-segment involvement in only 5 (3 with 
viability, 2 with ischemia), comprising apical anterior and 
apical lateral segments in 2 each and the proximal anterior 
septum in 1. Significant comorbidity and medical therapy were 
evenly distributed between patients with viability or ischemia 
and those with infarction only (Table 1). 
Of 45 patients with severe coronary disease at catheteriza- 
tion, 26 (58%) had jeopardized myocardium at dobutamine 
echocardiography (19 with ischemia [42%], 7 with viability 
[16%]). This relatively low rate of ischemia may be partially 
due to extensive previous infarction because the ejection 
fraction in this group was 27 _+ 4%. Furthermore, 15 (79%) of 
the 19 patients without jeopardized myocardium did not 
achieve 85% of age-predicted maximal heart rate compared 
with 40% in the overall group and 50% in the ischemic group 
with a submaximal heart rate response. 
Echocardiographic findings and hemodynamic responses to 
dobutamine for patients with viability or ischemia, or both, and 
those with infarction only are shown in Table 2. There was no 
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Table 1. Clinical Features of Patients With Ischemic or Viable Myocardium and Those With 
Myocardial Scar Only 
Overall Viab/Isc Scar p Value 
(n = 136) (n - 62) (n = 74) (scar vs. viab/isc) 
Age (yr) 67 + 7.9 66 + 7.5 68 +_ 7.9 NS 
Diabetes 56/136 (41) 25/62 (40) 31/74 (42) NS 
Hypertension 94/136 (69) 44/62 (71) 50/74 (68) NS 
Hypercholesterolemia 92/136 (68) 43/62 (69) 49/74 (66) NS 
Smoking 61/136 (45) 33/62 (53) 28/74 (38) 0.07 
Beta-blockers 19/136 (14) 8/62 (13) 11/74 (15) NS 
ACEI 70/l 36 (51) 30/61 (49) 40/74 (54) NS 
Nitrates 39/136 (29) 20/61 (33) 19/74 (26) NS 
Digoxin 28/136 (21) 9/61 (15) 19/74 (26) 0.11 
Data presented are mean value _+ SD or number (%) of patients. ACE1 - angiotensin-converting e zyme inhibitor; 
Viab/lsc - viable/ischemic myocardium. 
significant difference between the two groups with respect o 
left ventricular ejection fraction or rest left ventricular dimen- 
sions. 
The ECG ST segment changes were not predictive of either 
ischemia or viability. The ST segment response was nondiag- 
nostic in 56 patients (41%) (left bundle branch or intraventric- 
ular block in 26, left ventricular hypertrophy and ST segment 
changes in 21, diffuse ischemic hanges at rest or paced rhythm 
in 9). Symptoms of chest pain occurred in 25 patients; 9 
patients with pain and ST segment depression or elevation had 
an ischemic response confirmed on echocardiography. How- 
ever, of the remaining 16 patients with chest pain and no or 
uninterpretable ST segment changes, only 3 had ischemia 
detected on echocardiography. 
Cardiac events. Complete follow-up data were obtained 
for 130 patients (100 men, 30 women; mean age 68 _+ 10 years) 
over a period of 16 _+ 8 months. Six patients (4%) were lost to 
follow up (three from other states, two from overseas). The 
prevalence of viable or ischemic myocardium and other echo- 
cardiographic variables in the 6 patients lost to follow-up were 
similar to those in the remaining 130. 
Of the 130 patients, 22 were referred for intervention within 
3 months of dobutamine echocardiography (10for coronary 
angioplasty, 11 for bypass urgery, and 1 for cardiac transplan- 
tation). All 11 patients who underwent bypass surgery had 
evidence of myocardial ischemia or viability on dobutamine 
echocardiography, but only 4 of 10 patients undergoing coro- 
nary angioplasty had detectable ischemia or viability. Patients 
with intervention may have influenced the results of long-term 
follow up and were thus analyzed separately. Late cardiac 
death occurred in three patients (14%) who underwent inter- 
vention, and one required repeat coronary angioplasty within 6 
months of the index procedure. 
Of the remaining 108 patients who had medical therapy on 
an intention-to-treat b sis, 46 had viable or ischemic myocar- 
dium, and 62 had scar only on dobutamine echocardiography. 
In this group, there were 26 cardiac events in 26 patients (24%) 
(18 cardiac-related deaths due to myocardial infarction, con- 
gestive cardiac failure or arrhythmia; 4 nonfatal myocardial 
infarctions; 4episodes of unstable angina requiring late revas- 
cularization). Fourteen patients required subsequent hospital 
admission for congestive cardiac failure (eight patients) or 
angina (six patients), but in the absence of documented 
infarction or coronary intervention, these events were not 
considered cardiac end points. Of these 14 patients, 6 had 
evidence of myocardial viability or ischemia, and the remaining 
8 had myocardial scar alone. 
Table 3 summarizes the distribution of clinical variables in 
Table 2. Echocardiographic Features of Patients With lschemic or Viable Myocardium and Those 
With Myocardial Scar Only (mean _+ SD) 
Overall Viab/lsc Scar p Value 
(n - 136) (n - 62) (n - 74) (scar vs. viab/isc) 
LVEDV (ml) 171 _+ 44 174 _~ 43 169 _+ 44 NS 
LVESV (ml) 122 + 36 125 + 35 120 _+ 36 NS 
Ejection fraction (%) 30 _+ 5 29 _+ 5 30 -+ 6 NS 
Stroke volume (ml) 49 _+ 11 50 -- 11 49 _+ 11 NS 
Rest heart rate (beats/min) 77 -+ 11 75 _+ 11 79 -+ 11 NS 
Rest SBP (ram Hg) 138 + 23 138 _+ 21 138 + 25 NS 
Peak heart rate (beats/rain) 127 _+ 13 126 _+ 13 127 _+ 14 NS 
% age-predicted heart rate 83 - 9 82 _+ 8 83 -+ 9 NS 
Peak SBP (mm Hg) 141 _+ 28 139 _+ 27 143 + 29 NS 
LVEDV = left ventricular end-diastolic volume; LVESV - left ventricular end-systolic volume; SBP = systolic blood 
pressure; Viab/Isc - viable/ischemic myocardium. 
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Table 3. Clinical Features of Patients With and Without 
Cardiac Events loo 
Events No Events p 
(n - 26) (n = 82) Value 80 
Age (yr) 69 ± 6 68 + 8 NS 
60 
Diabetes 10 (38) 34 (41) NS 
Hypertension 19 (73) 61 (74) NS 
Hypercholesterolemia 18 (69) 55 (67) NS 40 
Smoking 17 (65) 31 (38) 0.01 
Beta-blockers 3 (12) 9 (11) NS 20 
ACEI 19 (73) 40 (49) 0.03 
Nitrates 4 (15) 22 (27) NS 0 
Digoxin 6 (23) 15 (18) NS 
Data presented are mean + SD or number (%) of patients. ACEI = 
angiotensin-converting e ~me inhibitor. 
medically treated patients with and without cardiac events. 
There was no significant difference between the prevalence of
risk factors or medication usage between patients with and 
without events, except hat smokers were disproportionately 
represented among patients with events. Likewise, analysis of 
echocardiographic variables, including left ventricular ejection 
fraction showed no significant difference between the two 
groups (Table 4). In patients with a cardiac event, there was a 
trend toward increased left ventricular end-diastolic (183 + 41 
vs. 167 _+ 44 ml) and end-systolic volume (130 _+ 37 vs. 119 _+ 
35 ml), but all other variables were similar. 
The peak dose of dobutamine (40 /xg/kg per rain) was 
achieved in 75 (69%) of 108 patients undergoing follow-up 
echocardiography. In the 33 patients with early termination of 
the test before maximal dobutamine dose, 11 had cardiac 
events compared with 15 events in the 91 patients with the 
maximal dobutamine dose (33% vs. 20%, p = 0.04). Similarly, 
63 (58%) of 108 patients followed up for primary cardiac 
events achieved >85% of age-predicted maximal heart rate, 
and 45 (42%) had a submaximal heart rate response. There 
were 16 cardiac events in the 45 patients with inadequate heart 
rate response as opposed to 10 events in the 63 patients with 
adequate heart rate response (36% vs. 16%, p = 0.02). In the 
Table 4. Echocardiographic Features of Patients With and 
Without Cardiac Events 
Events No Events p 
(n = 26) (n = 82) Value 
LVEDV (ml) 183 - 41 167 + 44 NS 
LVESV (ml) 130 ± 37 119 _+ 35 NS 
Ejection fraction (%) 29 _+ 6 30 ± 5 NS 
Stroke volume (ml) 52 + 9 48 ± 12 NS 
Rest heart rate (beats/rain) 76 ± 11 77 ± 11 NS 
Rest SBP (ram Hg) 136 ± 25 14(1 ± 23 NS 
Peak heart rate (beats/min) 121 + 13 128 = 14 NS 
% age-predicted heart rate 80 _+ 8 84 _+ 8 NS 
Peak SBP (ram Hg) 135 _+ 25 144 _+ 29 NS 
Viab/lsc myocardium 20 (77%) 26 (32%) < 0.0001 
Data presented are mean ± SD or number (%) of patients. Abbreviations 
as in Table 2. 
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Figure l. Life table demonstrating event rates in patients with infarc- 
tion only (Scar) and those with viable or ischemic myocardium 
(VM/ISC). 
45 patients not attaining 85% age-predicted maximal heart 
rate, 21 had evidence of ischemia or viability as opposed to 23 
of the 63 patients with adequate heart rate response (47% vs. 
37%, p = 0.29). In the group with inadequate heart rate, the 
finding of echocardiographic, ECG or symptomatic ischemia 
often led to termination of the test before attainment of target 
heart rate and may account at least in part for the bias toward 
ischemia/viability and events in this group. 
Relation between dobutamine chocardiography and car- 
diac events. Of 26 medically treated patients with an event, 20 
(77%) had myocardial viability or ischemia detected uring 
dobutamine chocardiography, and 6 (23%) had myocardial 
scar only. The event rate was greater in patients with viable or 
ischemic myocardium than in those with scar (43% vs. 8%, p = 
0.01), and Kaplan-Meier survival analysis confirmed a signifi- 
cantly worse outcome (p = 0.01 by log-rank test) in the group 
with viability or ischemia than in the group with scar (Fig. 1). 
In a Cox regression model that included age, left ventricular 
ejection fraction and presence of ischemic or viable myocar- 
dium, the presence of viability or ischemia was found to predict 
subsequent events (adjusted relative risk 3.5, 95% confidence 
interval 0.10 to 0.80, p = 0.02), independent of ejection 
fraction or age (Table 5). Moreover, although analysis of the 
overall group of 46 patients with viability or ischemia showed 
an increased prevalence of cardiac events, subgroup analysis 
showed no significant difference between patients with viability 
and ischemia with respect to cardiac events (Fig. 2). 
The relation of dobutamine chocardiographic results to 
Table 5. Cox Proportional Hazards Model Results for Relative Risk 
of Viable or Ischemic Myocardium, Age and Ejection Fraction 
Relative p 
Risk Value 
Viability./ischemia 3.51 0.02 
Age 1.03 0.28 
Ejection fraction 1 0.88 
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Figure 2. Comparison fevent rates in patients with viable or ischemic 
myocardium. 
outcome appeared to be unrelated to reason for testing. Of 53 
patients who underwent testing for preoperative risk strati- 
fication, 22 (42%) had evidence of viable or ischemic myo- 
cardium. Twelve (46%) of these 22 patients had their man- 
agement strategy altered by the results of dobutamine 
echocardiography (operation deferred in 4 pending coronary 
intervention, operation canceled in 5, operative strategy sim- 
plified in 3). Of 48 patients proceeding with noncardiac 
(predominantly vascular) surgery, 10 had viable or ischemic 
myocardium. No perioperative cardiac-related deaths or myo- 
cardial infarctions occurred in this group. Of 11 patients with 
atrial arrhythmias or exacerbation fcongestive cardiac failure 
in the perioperative period, only 3 had myocardial viability or 
ischemia at dobutamine study, but left ventricular ejection 
fraction (24%) was lower in this group. At long-term follow-up, 
10 (19%) of 53 patients experienced a cardiac event; 7 of 9 with 
a cardiac-related death and i with late coronary angioplasty in
this subgroup had viable or ischemic myocardium on dobut- 
amine echocardiography. This event rate was not significantly 
different from that in the remaining patients. 
Discuss ion  
The results of the present study show that the presence of 
viable or ischemic myocardium detected at dobutamine echo- 
cardiography in patients with left ventricular dysfunction is 
related to an increased incidence of cardiac events at long-term 
follow-up among those receiving medical therapy. Moreover, 
this finding appears to be independent of age and left ventric- 
ular ejection fraction. To our knowledge, the prognostic sig- 
nificance of viability detected by dobutamine chocardiogra- 
phy has not been shown previously. 
Prognostic significance of ischemia at stress echocardiog- 
raphy. In different clinical scenarios, with different stress 
modalities, the finding of ischemia at stress echocardiography 
has been associated with subsequent cardiac events and an 
adverse long-term outcome, whereas the absence of ischemia 
implies a more favorable long-term prognosis (22). Among 360 
patients with overall normal left ventricular function who 
underwent treadmill stress echocardiography, Krivokapich et 
al. (23) showed a threefold increase in the incidence of cardiac 
events in patients with positive stress echocardiographic re- 
sponses. Similarly, Severi et al. (24) showed that ischemia 
during dipyridamole chocardiography as incremental prog- 
nostic benefit above and beyond that provided by routine 
exercise stress electrocardiography. Ischemia at dobutamine 
echocardiography may be used to identify patients with a 
greater likelihood of future cardiac events in groups with a 
high pretest probability of coronary disease (25), patients with 
stable long-term coronary disease (26) and patients undergo- 
ing major vascular surgery (15-17). Thus, the existing data 
indicate that in patients with essentially normal ventricular 
function, an ischemic response at dobutamine chocardiogra- 
phy implies a poorer prognosis. 
Prognostic significance of viable myocardium. Viable myo- 
cardium may be identified by positron emission tomography 
(PET) (27,28), and the presence of either viable or ischemic 
myocardium detected by PET is associated with subsequent 
cardiac events in patients who do not undergo myocardial 
revascularization. The response of dysfunctional myocardium 
to low doses of dobutamine (5 to 10/~g/kg per min) is also 
indicative of viable myocardium (29), and findings consistent 
with myocardial viability at PET have been shown to correlate 
with the results of dobutamine echocardiography. The results 
of the present study suggest that the prognostic implications of 
viability or ischemia at dobutamine chocardiography are 
comparable to those reported with PET. Moreover, the prog- 
nostic implications of viable myocardium at dobutamine echo- 
cardiography (which demonstrates improvement a  low doses 
or a biphasic improvement with subsequent deterioration) 
were comparable to those of ischemic tissue in the present 
study. 
Although the relation of these findings to the underlying 
pathophysiologic mechanisms ofviable myocardium is unclear, 
the similar behavior of perfusion-metabolism ismatch, 
"dobutamine-viable" and "dobutamine-ischemic" tissues 
might suggest hat these states may not be as separate as has 
been traditionally implied. Indeed, teleologically, the adverse 
outcome of patients with ischemic segments might be ex- 
plained if the area acts as a substrate for malignant arrhyth- 
mias, subsequent myocardial infarction (leading to deteri- 
orating left ventricular function), or remodeling. All these 
phenomena may be explained if the segment is perceived as a 
jeopardized region, corresponding to the presence of incom- 
plete infarction (30). 
Clinical significance. In addition to the major end points in 
the present study (death, myocardial infarction and unstable 
angina requiring revascularization), "soft" end points, such as 
hospital admission with cardiac failure or milder exacerbations 
of angina, are a continuing burden with respect to the cost of 
medical treatment. However, we did not use these soft end 
points or symptom analyses in our study, because of the varying 
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thresholds of both medical and nonmedical guidelines for 
admission in these circumstances. 
The natural history of patients with ischemic cardiomyo- 
pathy is associated with a very poor long-term outcome (31,32), 
and the risk of bypass surgery is certainly greater than that in 
patients with normal ventricular function (33). Nonetheless, 
large studies of myocardial revascularization (32) have shown 
that the use of bypass surgery to treat ischemia in patients with 
severe left ventricular dysfunction is associated with improve- 
ment in survival. Uncontrolled studies based on PET data 
suggest hat the revascularization of viable segments hould 
also be considered on prognostic grounds. Whether the same 
benefit of revascularization can be shown for viable segments 
demonstrated by dobutamine chocardiography remains to be 
defined; we studied a group with more end-stage disease and a 
relatively low rate of surgical revascularization, which inhibited 
our ability to demonstrate a prognostic benefit in favor of 
revascularization. 
Many patients with viable myocardium in the present study 
were unsuitable for myocardial revascularization because of 
other medical problems. In patients undergoing medical treat- 
ment, the therapeutic implications of finding viable and isch- 
emic myocardium remain to be defined. In particular, the 
prognostic benefits of therapy with angiotensin-converting 
enzyme inhibitors or low doses of beta-blockers in the presence 
of jeopardized myocardium are uncertain. Currently, there- 
fore, the only intervention that appears to influence outcome 
in patients with viable and ischemic myocardium is myocardial 
revascularization. 
Study limitations. 1) The present study included a hetero- 
geneous group of patients with various etiologies of left 
ventricular dysfunction. Although most patients had significant 
coronary disease by ECG, echocardiographic and coronary 
angiographic riteria, we could not ascertain an ischemic 
etiology of left ventricular dysfunction in all patients. Indeed, 
even in patients with coronary disease (especially if there is a 
discrepancy between the extent of disease and the severity of 
left ventricular dysfunction), it may be difficult to ascertain 
whether left ventricular dysfunction is due to ischemia/infarc- 
tion rather than hypertension, diabetes or another cause. Thus, 
selection of patients with purely ischemic ventricular dysfunc- 
tion may be difficult. Nonetheless, the present study design has 
the advantage of mimicking the use of dobutamine chocardi- 
ography in clinical practice to identify the presence of an 
ischemic component in patients with left ventricular dysfunc- 
tion of unknown cause. 2) The group largely comprised elderly 
patients with significant left ventricular dysfunction, and the 
presence of a relatively narrow range for both age and ejection 
fraction may explain the apparent lack of influence of both 
these variables on outcome. Caution should be used in the 
extrapolation of these data to other patient groups; for exam- 
ple, the referral pattern for dobutamine chocardiography ata 
tertiary care hospital may not parallel the patients studied in 
office practice. 
Conclusions. Dobutamine echocardiography may be used 
to identify ischemic and viable myocardium. The results of the 
present study indicate that medical treatment of patients with 
jeopardized myocardium is associated with subsequent events, 
independent of other prognostic factors, including age and left 
ventricular function. 
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